Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Haemonetics Corp (NY: HAE )

89.39 +0.46 (+0.52%)
Streaming Delayed Price Updated: 10:17 AM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corp

< Previous 1 2 3 4 Next >
NYSE:HAE stands out as a growth opportunity that won't break the bank.
NYSE:HAE is not too expensive for the growth it is showing. 
Via Chartmill
Looking for growth without the hefty price tag? Consider NYSE:HAE.
HAEMONETICS CORP/MASS (NYSE:HAE) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112. 
Via Benzinga
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
These 3 Companies Boast Bright Outlooks
Favorable earnings estimate revisions are key for a stock to move higher. Let’s examine a few highly ranked stocks, including Stride, Interactive Brokers, and Haemonetics. 
Via Talk Markets
NYSE:HAE, a growth stock which is not overvalued.
Despite its growth, HAEMONETICS CORP/MASS (NYSE:HAE) remains within the realm of affordability. 
Via Chartmill
4 Analysts Assess Haemonetics: What You Need To Know
Via Benzinga
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
Is HAEMONETICS CORP/MASS (NYSE:HAE) suited for quality investing?
Why the quality investor may take a look at HAEMONETICS CORP/MASS (NYSE:HAE). 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
HAE Stock Earnings: Haemonetics Beats EPS, Beats Revenue for Q4 2024
HAE stock results show that Haemonetics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024. 
Via InvestorPlace
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. 
Via Chartmill
Intuitive Surgical Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Intuitive Surgical stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 74 to 85. 
Via Investor's Business Daily
Intuitive Surgical Stock Rating Climbs As Sales, Profits Rise
Intuitive Surgical stock got an IBD rating upgrade Monday. It edged up 0.37% to 274.16, its second day in a row of rising share price. 
Via Investor's Business Daily
Exploring NYSE:HAE's quality characteristics.
Should you consider HAEMONETICS CORP/MASS (NYSE:HAE) for quality investing? 
Via Chartmill
Should you consider NYSE:HAE for quality investing?
HAEMONETICS CORP/MASS (NYSE:HAE) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
4 Analysts Have This to Say About Haemonetics
Via Benzinga
Haemonetics Earnings Preview
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Intuitive Surgical Stock Nearly Doubles; Gets Rating Upgrade
Intuitive Surgical stock dipped to an intraday low 180.07 in October last year as the bear market ended, then shot up to 358.07 on July 19. 
Via Investor's Business Daily
Haemonetics Corp. (NYSE: HAE) Making Surprising Moves in Monday Session
Via Investor Brand Network
Haemonetics Q4 Earnings Exceed Expectations On Volume And Price Benefits
Via Benzinga
Recap: Haemonetics Q4 Earnings
Via Benzinga
Looking Into Haemonetics's Return On Capital Employed
Via Benzinga
Alphabet To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Wednesday
Loop Capital boosted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $120 to $125. Loop Capital analyst Rob Sanderson maintained a Buy rating. Alphabet shares fell 3.7% to $103.70 in pre-market... 
Via Benzinga
Earnings Preview: Haemonetics
Via Benzinga
Where Haemonetics Stands With Analysts
Via Benzinga
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled. 
Via Investor's Business Daily
How 2022's Biggest Healthcare Gainers Could Fare In 2023
Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023 
Via MarketBeat
9 Analysts Have This to Say About Haemonetics
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.